

**Title: Performance of a high-intensity 508-gene circulating-tumor DNA (ctDNA) assay in patients with metastatic breast, lung, and prostate cancer**

**Authors:** Pedram Razavi<sup>1</sup>, Bob T. Li<sup>1</sup>, Wassim Abida<sup>1</sup>, Alex Aravanis<sup>2</sup>, Byoungsok Jung<sup>2</sup>, Ronglai Shen<sup>1</sup>, Chenlu Hou<sup>2</sup>, Ino De Bruijn<sup>1</sup>, Sante Gnerre<sup>2</sup>, Raymond S. Lim<sup>1</sup>, Dalicia Reales<sup>1</sup>, Tara Maddala<sup>2</sup>, Michael F. Berger<sup>1</sup>, Gregory J. Riely<sup>1</sup>, Howard I. Scher<sup>1</sup>, William F. Novotny<sup>2</sup>, David B. Solit<sup>1</sup>, Mark Lee<sup>2</sup>, Jorge S. Reis-Filho<sup>1</sup>, Jose Baselga<sup>1</sup>

**Affiliations:** <sup>1</sup>Memorial Sloan Kettering Cancer Center, New York, NY <sup>2</sup>GRAIL, Inc., Menlo Park, CA

**Disclosures:** Pedram Razavi received institutional research funding from GRAIL, Inc. Bob T. Li received institutional research funding from AstraZeneca, BioMed Valley Discoveries, GRAIL, Inc., Illumina, and Roche/Genentech; and received consulting/advisory fees from Biosceptre International, Roche, and Thermo Fisher Scientific. Wassim Abida received honorarium from CARET, consulting/advisory fees from Clovis Oncology, and research funding from AstraZeneca and Zenith Epigenetics. Alex Aravanis, Byoungsok Jung, Chenlu Hou, Sante Gnerre, Tara Maddala, and William F. Novotny are or were employees of GRAIL, Inc. with stock or other ownership interests in the company. Sante Gnerre holds stock or other ownership interests in Illumina. Michael F. Berger received research funding from Illumina, and consulting/advisory fees from Cancer Genetics and Sequenom. Gregory J. Riely received consulting/advisory fees from Genentech, Novartis, and Roche; received institutional research funding from ARIAD, GlaxoSmithKline, Infinity Pharmaceuticals, Millenium, Novartis, Pfizer, and Roche/Genentech; and received compensation for travel, accommodations, and/or expenses from Novartis. Howard I. Scher received consulting or advisory fees from Astellas Pharma, Blue Earth Diagnostics, Clovis Oncology, Elsevier, Ferring, Janssen Research and Development, Med IQ, Medivation, Merck, Roche, Sanofi, and WIRB-Copernicus Group; has a leadership role with Asterias Biotherapeutics; received institutional research funding from Illumina, Innocrin Pharma, Janssen, and Medivation; and received compensation for travel, accommodations, and/or expenses from Astellas Pharma, Ferrings, Medivation, Roche, and WIRB-Copernicus Group. David B. Solit received honoraria as well as consulting and/or advisory fees from Loxo and Pfizer. Mark Lee is or was an employee of Boreal Genomics, Genomic Health, Google Life Sciences, and GRAIL, Inc.; has a leadership role with Boreal Genomics; has stock or other ownership interests in Boreal Genomics, Genomic Health, Google Life Sciences, and GRAIL, Inc.; and holds patents or other intellectual property, or has received royalties from, Genomic Health. Jorge Reis-Filho received consulting/advisory fees from VolitionRX. Jose Baselga has a leadership role (e.g., Board of Directors) with Infinity Pharmaceuticals, Varian Medical Systems, and GRAIL, Inc. (former board member); holds stock or other ownership interests in GRAIL, Inc., Infinity Pharmaceuticals, Juno Therapeutics, PMV Pharma, and Varian Medical Systems; and received consulting or advisory fees from Eli Lilly, Novartis, and GRAIL, Inc. The remaining authors have nothing to disclose.